STL Index for: Guselkumab
Psoriasis Education Tool for Patient-Physician Decision-Making About Biologics: A Pilot Study
Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.
Skin Treatments Introduced in 2020
This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.
Update on Drugs & Devices: September-October 2020
This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)
Update on Drugs & Devices: May – June 2019
Latest drug update covers Pembrolizumab for IV injection (Keytruda®, Merck & Co.), Guselkumab for SC injection (Tremfya®, MorphoSys/Janssen), Dupilumub for SC injection (Dupixent®, Regeneron), and Risankizumab for SC injection (Skyrizi™, AbbVie).
Skin Treatments Introduced in 2017
A look back at skin treatments introduced in 2017 for the following type/class of therapy: Antibiotic agents, anti-cancer agents, atopic dermatitis, dermal fillers, fabry disease, hereditary angioedema, herpes zoster, hidradenitis suppurativa, psoriasis, psoriatic arthritis, rosacea...
Update on Drugs and Drug News: September-October 2017
September-October 2017 Update on drugs include Isopropyl myristate solution Resultz®, Delafloxacin oral and IV formulations Baxdela™, Plasma-derived concentrate of C1 esterase inhibitor SC (human) Haegarda®, Oral dimethyl fumarate Skilarence®, Abatacept for IV or SC injection Orencia®, Consentyx®, Tremfya™, Yervoy® and Benlysta®.
A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis
Psoriasis is thought to arise from a combination of pathogenic factors including genetic susceptibility and environmental exacerbation. This article reviews the current status of guselkumab as a therapy for moderate-to-severe plaque psoriasis.
Interleukin-23 in the Pathogenesis and Treatment of Psoriasis
In the past three decades, major advances have been made in understanding the pathogenesis of psoriasis. This review focuses on the role of IL-23 in psoriasis pathogenesis and the current therapies targeting IL-23 that are being studied in clinical trials.
